Research summary ·
From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This was a systematic review of testicular germ cell tumors. These are cancers that start in the testicle. The authors looked for markers that may show how the cancer behaves. Some may also show how well a treatment will work. They searched research databases up to 6 July 2026. They also used registry data, reference lists and current guidelines.
What they found
The review covered blood, tissue and immune markers. It also looked at tiny genetic pieces in blood called microRNAs. Each marker was graded as well proven, under research, or still new. A blood test called miR-371a-3p did well at finding active cancer. Its pooled sensitivity was about 0.90. Its specificity was about 0.86. But it did not pick up pure teratoma, one tumor type. The usual blood tests AFP, β-hCG and LDH are still needed. Doctors use them to stage the cancer and set risk groups.
What it means for patients
The authors note that marker-based care looks hopeful. Still, no single marker has yet proved useful enough to replace current care. Doctors still judge these tumors with many checks together. These include how the tumor looks under a microscope. They also include stage, tumor type, scans and blood markers. Known risk models are part of this as well.
Why it is not certain yet
A review can only be as good as the studies in it. Some markers were graded only as new candidates. The authors say no single marker is yet useful enough on its own. The miR-371a-3p test misses pure teratoma. The abstract does not say how many studies were included. It also gives few numbers for the other markers.
Source
From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
PubMed · PMID 42930552We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Testicular cancer publications